The study authors enrolled patients in a prospective, multicenter surgical database. The patients either received autologous infusion from cell saver during surgery, or had cell saver available but didn’t undergo intraoperative autologous infusion. Here are five key findings:
1. The 427 patients in the infusion group had a higher percentage of estimated blood loss relative to estimated blood volume at 42.2 percent when compared with the non-infusion group at 19.6 percent. The infusion group patients received 698 mL autologous infusion on average.
2. Demographics between both groups were similar, and there were 153 patients in the no infusion group. The allogeneic transfusion was more common in the infusion group at 60 percent than the no infusion group, at 44 percent.
3. Patients in the infusion group received more allogeneic blood units transfused on average than the non-infusion group.
4. Blood costs for the non-infusion group ranged from $396 to $2,146; in the infusion group, blood costs ranged from $1,262 to $5,088. However, transforming the cell saver costs to allogeneic blood costs, the total blood costs for the infusion group were $840 to $5,418.
5. The cell saver had an average cost savings of $330 to $422, and a linear regression shows cell saver is cost-efficient after an estimated blood loss of 614 mL.
More articles on spine surgery:
5 findings on cement-augmented screws for spinal fusion in low bone quality patients
Florida Hospital Tampa enhances offerings with Brain & Spine Institute: 5 things to know
5 key recommendations for payer freeform in spine surgery
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
